New Age Alpha Advisors LLC Invests $43,000 in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,816 shares of the company’s stock, valued at approximately $43,000.

Several other institutional investors have also modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock worth $338,989,000 after buying an additional 22,044,407 shares during the last quarter. Duquesne Family Office LLC grew its stake in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company’s stock valued at $96,078,000 after purchasing an additional 5,186,592 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company’s stock valued at $91,973,000 after purchasing an additional 4,824,247 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Teva Pharmaceutical Industries by 87.8% in the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock valued at $113,625,000 after purchasing an additional 2,410,420 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TEVA. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 target price on the stock. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Truist Financial started coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Bank of America boosted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Buy” and a consensus target price of $24.71.

Teva Pharmaceutical Industries Stock Up 0.3%

Shares of Teva Pharmaceutical Industries stock opened at $16.41 on Tuesday. The business has a 50-day moving average of $16.70 and a 200-day moving average of $16.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The company has a market capitalization of $18.83 billion, a PE ratio of -102.58, a P/E/G ratio of 0.97 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company’s revenue was up .3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 EPS. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 65,001 shares of company stock valued at $996,958 in the last quarter. Company insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.